| December 4, 2023 |
Timely Disclosure Information
|
StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
|
| November 16, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
|
| November 16, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023
|
| October 27, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Change of Representative Directors
|
| September 28, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
|
| September 28, 2023 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator
|
| September 20, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee
|
| September 20, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director
|
| September 19, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee
|
| September 19, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director
|
| September 6, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy (Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Hypertensive Cardiomyopathy)
|
| September 4, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| July 31, 2023 |
Timely Disclosure Information
|
StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan)
|
| July 25, 2023 |
Timely Disclosure Information
|
StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China)
|
| July 18, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
